Understand the source comparison
Peptides for Ligament Repair: Research vs Clinical Evidence
BPC-157 VEGF receptor activation, fibroblast recruitment, collagen synthesis Strong preclinical (rat/rabbit models), no human RCTs 10–50 mcg/kg daily Most studied for ligament/tendon repair. Mechanism is well-characterized, human data pending TB-500 (Thymosin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF receptor activation, fibroblast recruitment, collagen synthesis
- Strong preclinical (rat/rabbit models), no human RCTs
- 10–50 mcg/kg daily
- Most studied for ligament/tendon repair. Mechanism is well-characterized, human data pending
- TB-500 (Thymosin Beta-4)
- Actin upregulation, cell migration, angiogenesis, anti-fibrotic signaling
- Moderate preclinical, limited human trials
- 2–10 mg total weekly
- Strong for soft tissue injury. Less ligament-specific data than BPC-157 but overlapping pathways
- GHK-Cu
- Collagen synthesis, MMP modulation, wound healing gene activation
- Moderate preclinical, dermal studies in humans
- 1–3 mg daily (systemic)
- Better studied in skin repair. Ligament applications are mechanistically sound but less validated
- Growth Hormone Secretagogues (e.g., Ipamorelin, MK 677)
- Indirect. Elevate IGF-1, which supports collagen synthesis and anabolic signaling
- Weak for ligament-specific outcomes. General tissue repair support
- Varies widely by compound
- Useful as systemic support. Not a primary ligament repair agent
- Here's the honest answer: the bulk of peptide evidence for ligament repair comes from animal models. Not human clinical trials. That doesn't mean the peptides don't work. It means regulatory and funding barriers have kept large-scale human trials from happening. The mechanisms are conserved across mammalian biology, and the preclinical data is compelling, but claiming 'clinical proof' would overstate what exists in peer-reviewed literature as of 2026.
- What we have: dozens of rodent and rabbit studies showing accelerated healing times, higher tensile strength, and improved tissue organization. What we don't have: double-blind, placebo-controlled human trials measuring ligament healing with peptide intervention. That gap matters for regulatory approval. It doesn't negate the biological plausibility or preclinical outcomes.